Abstract Objectives We compared the clinicopathologic features, clinical management, and outcomes of human epidermal growth factor receptor 2 (HER2)–expressing nonexpressing microinvasive breast carcinomas (MiBC) to explore significance HER2 in MiBC. Methods Clinicopathologic follow-up information cases with final diagnosis MiBC known status between 2007 2019 were analyzed. Results Nineteen (41...

Objective(s): Breast cancer is one of the most common cancers in the world and is on the increase. MUC1 and HER2 as tumor-associated antigens (TAAs) are abnormally expressed to some extent in 75–80% of breast cancers.  In our present research, a novel chimeric MUC1-HER2 (HM) protein was designed and used to study whether an immune response can be generated against these TAAs. In vitro analysis ...

In this study, we synthesized Herceptin conjugated magnetic nanoparticles (HMNs) as an alternative probe to discover the levels of HER2 (Human epidermal growth factor receptor-2) in the surface of cells. These nanoparticles can be used by magnetic resonance imaging (MRI) (non-invasive methods) for screening the patients with HER2 positive or negative tumors. Dextran coated iron oxide nanopartic...

BACKGROUND The eligibility of breast cancer patients for human epidermal growth factor receptor 2 (HER2)-directed therapies is determined by the HER2 gene amplification and/or HER2 protein overexpression status of the breast tumor as determined by in situ hybridization (ISH) or immunohistochemistry (IHC), respectively. Our objective was to combine the US Food and Drug Administration (FDA)-appro...

The results of clinical trials evaluating the efficacy of HER2 inhibitors in patients with breast cancer indicate that the correlation between HER2 receptor levels and patient outcomes is as low as 50%. The relatively weak correlation between HER2 status and response to HER2-targeting drugs suggests that measurement of HER2 signaling activity, rather than absolute HER2 levels, may more accurate...

ABSTRACT HER2-targeted therapy with the HER2 monoclonal antibody trastuzumab has achieved impressive outcomes in first-line settings of patients advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma overexpressing HER2. However, considering that a substantial proportion those eventually relapses, as well relatively limited performance agents second-line settings, deeper understand...

background : mdm2, e-cadherin, survivin and her2 genes are involved in the regulation of normal cell growth. however, any crucial change in their expression levels can convert a normal cell into a cancer cell. numerous studies have identified alterations of these gene expression levels in various cancers, particularly in breast cancer. thus, they may be used as diagnostic biomarkers. in this ex...

Background: Elucidating the clinical features of metastatic breast cancer (MBC) patients with an exceptionally favorable prognosis may offer insights to improve survival more typical patients. Methods: We collected comprehensive real-world data on clinicopathologic characteristics, treatments, and outcomes 110 consecutive MBC who survived for over ten years from warehouse Samsung Medical Center...